Nissay Asset Management Corp Japan ADV Boosts Stake in Alexion Pharmaceuticals, Inc. (ALXN)

Nissay Asset Management Corp Japan ADV lifted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 26,902 shares of the biopharmaceutical company’s stock after acquiring an additional 624 shares during the quarter. Nissay Asset Management Corp Japan ADV’s holdings in Alexion Pharmaceuticals were worth $3,740,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ALXN. First Hawaiian Bank purchased a new stake in Alexion Pharmaceuticals during the 3rd quarter worth about $102,000. Advisory Services Network LLC lifted its holdings in Alexion Pharmaceuticals by 145.3% during the 2nd quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 523 shares in the last quarter. Checchi Capital Advisers LLC purchased a new stake in Alexion Pharmaceuticals during the 3rd quarter worth about $204,000. Berson & Corrado Investment Advisors LLC purchased a new stake in Alexion Pharmaceuticals during the 2nd quarter worth about $205,000. Finally, K.J. Harrison & Partners Inc purchased a new stake in Alexion Pharmaceuticals during the 3rd quarter worth about $209,000. Institutional investors own 92.94% of the company’s stock.

A number of analysts recently issued reports on the company. Credit Suisse Group set a $156.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $134.00 price objective on the stock in a report on Tuesday. Citigroup dropped their price objective on Alexion Pharmaceuticals from $195.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, October 25th. Leerink Swann set a $181.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, October 24th. Finally, Morgan Stanley increased their price objective on Alexion Pharmaceuticals from $157.00 to $165.00 and gave the stock an “overweight” rating in a report on Thursday, October 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $161.29.

NASDAQ:ALXN opened at $122.82 on Friday. Alexion Pharmaceuticals, Inc. has a twelve month low of $102.10 and a twelve month high of $140.77. The stock has a market capitalization of $25.00 billion, a price-to-earnings ratio of 17.11, a price-to-earnings-growth ratio of 0.97 and a beta of 0.99. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.74 and a current ratio of 3.16.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.28. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter last year, the firm posted $1.44 EPS. The company’s revenue was up 19.5% compared to the same quarter last year. As a group, research analysts expect that Alexion Pharmaceuticals, Inc. will post 6.82 earnings per share for the current fiscal year.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Story: Investing strategies using the yield curve

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply